GBMA publishes quarterly review of biosimilar literature

Home/Reports | Posted 15/05/2020 post-comment0 Post your comment

The Generic and Biosimilar Medicines Association (GBMA), which is the representative body of generic and biosimilar medicine suppliers in Australia, has released its quarterly review of biosimilar literature [1].

20 AA010933

The review, which covers the period from 1 October to 31 December 2019, was produced by authors from the University of South Australia’s School of Pharmacy and Medical Sciences; and was released on 10 March 2020.

The report provides an update to the comprehensive literature search previously conducted on behalf of Australia’s Department of Health. To inform activities related to the GBMA Education’s Biosimilar Education Grant, these reviews examine all international and Australian clinical, academic and policy journals in relation to biosimilars.

The reviews focus on four key topics:

  • Comparability of biosimilars to originator biologicals (access and substitution)
  • Uptake of biosimilars
  • Pharmacovigilance (health outcomes and adverse events)
  • Perceptions towards biosimilars

During this review period the authors identified 12 phase I and III studies, as well as six pharmacoeconomic studies that are related to the access and substitution of biosimilars. They identified eight studies covering infliximab, etanercept, rituximab, filgrastim and erythropoietin that contained information about the uptake of biosimilars. They also identified nine studies with information on health outcomes and adverse events and seven studies covering patient perceptions and one study covering the perceptions of healthcare professionals.

Conflict of interest
The authors of the research paper [1] did not provide any conflict of interest statement.

Editor’s comment
Readers interested to learn more about uptake, pharmacovigilance and perceptions of biosimilars are invited to visit to view the following manuscripts published in GaBI Journal:

Improving biosimilars uptake: experience gained in Madrid, Spain

Pharmacovigilance, traceability and building trust in biosimilar medicines

Effect of naming on pharmacists’ perceptions and dispensing of biosimilars

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal platform – please send us your submission here.

Related article
New biosimilar guide for pharmacists in Australia

1. Ward M, Lange SR, Staff K. International biosimilar medicines. Review of the literature: quarterly update: October – December 2019. School of Pharmacy and Medical Sciences, University of South Australia. 10 March 2020.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010